Diabetes Australia supporting research into cardiovascular health 8 October 2019 A new class of diabetes drugs – SGLT 2 inhibitors could have a range of benefits for cardiovascular health. With the support of a grant from the Diabetes Australia Research Trust Associate Professor Neale Cohen, from the Baker Heart and Diabetes Institute, is trying to find new therapies to improve the health of people with diabetes. SGLT2 inhibitors work by helping the kidneys lower blood glucose levels. “Recent studies into SGLT2 inhibitors have found benefits to heart health, however at this stage we don’t really understand how those benefits work,” Associate Professor Cohen said. “We want to understand how these drugs help the heart, and if they might have benefits for the heart over and above their ability to lower blood glucose levels.”
News 3 April 2025 Public warning: Counterfeit Ozempic pens detected in Australia The Therapeutic Goods Administration (TGA) is urging the diabetes community to remain alert following the detection of counterfeit Ozempic-labelled injection... Continue Reading
News 20 March 2025 Government moves to reduce the cost of PBS medicines The Federal Government has today announced that medicines on the Pharmaceutical Benefits Scheme (PBS) will cost no more than $25... Continue Reading
News 18 December 2024 Ozempic supply to remain limited in 2025 Ozempic supply will continue to be limited until the end of 2025, according to the latest advice from Novo Nordisk,... Continue Reading